Skip to main content

Table 1 Summary of clinical trial patients and arms

From: Comprehensive analysis of treatment response phenotypes in rheumatoid arthritis for pharmacogenetic studies

  GOL PBO-NE PBO-EE
Number of patients 287 99 50
Female (%) 231 (0.8) 72 (0.73) 41 (0.82)
Age (SD) 51.92 (11.94) 52.77 (11.17) 49.24 (11.84)
Disease duration (SD) 7.19 (6.82) 7.64 (8.16) 6.56 (6.06)
BMI (SD) 27.19 (5.74) 26.88 (5.36) 26.73 (6.65)
Initial DAS (SD) 5.97 (0.81) 5.87 (1.02) 5.93 (0.8)
RF positive (%) 265 (0.92) 91 (0.92) 45 (0.9)
ACPA positive (%) 262 (0.91) 92 (0.93) 48 (0.96)
Number of visits (SD) 15.03 (2.7) 14.65 (3.18) 15.76 (0.72)
Number removed (%) a 5 (2) 10 (10) 0 (0)
  1. GOL includes patients randomized to GOL treatment at week 0. PBO-NE includes patients randomized to PBO at week 0 who did not qualify for the early escape protocol. PBO-EE includes patients randomized to PBO at week 0 who qualified for the early escape protocol
  2. ACPA anti-citrulinated peptide antibody, BMI body mass index, DAS Disease Activity Score, EE early escape, GOL golimumab, NE non-early escape, PBO placebo, RF rheumatoid factor, SD standard deviation
  3. aPatients from any arm who dropped out within 4 weeks of initial GOL treatment were removed from analyses